Scroll Top

Mavacamten Shows Promise in Heart Failure With Normal to Supranormal EF

Mavacamten Shows Promise in Heart Failure With Normal to Supranormal EF

MedPage Today) — There may be a future for cardiac myosin inhibitors in heart failure with preserved ejection fraction (HFpEF), according to the proof-of-concept EMBARK-HFpEF trial.
An established cardiac myosin inhibitor for hypertrophic cardiomyopathy…
Read More

Leave a comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.